MX2009013937A - Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. - Google Patents

Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.

Info

Publication number
MX2009013937A
MX2009013937A MX2009013937A MX2009013937A MX2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A MX 2009013937 A MX2009013937 A MX 2009013937A
Authority
MX
Mexico
Prior art keywords
hypertension
new use
chemical compounds
pharmacologically active
arterial
Prior art date
Application number
MX2009013937A
Other languages
English (en)
Inventor
Stefan G Pierzynowski
Original Assignee
Entress Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entress Ab filed Critical Entress Ab
Publication of MX2009013937A publication Critical patent/MX2009013937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invenci?n se relaciona con el nuevo uso de alfa-cetoglutarato, amidas y sales y mezclas de los mismos para la fabricaci?n de una preparaci?n farmac?utica o complemento para alimento o forraje para el mejoramiento terap?utico in vivo de la elasticidad de vasos sangu?neos, en particular, la elasticidad arterial en un sujeto en necesidad del mismo. El mejoramiento de la elasticidad de los vasos sangu?neos puede utilizarse para el tratamiento y/o profilaxis de la hipertensi?n, hipertensi?n arterial pulmonar, enfermedad cardiovascular, enfermedad vascular retiniana, insuficiencia cardiaca, arterosclerosis, hipertrofia ventricular, accidente cerebrovascular, aneurisma arterial, insuficiencia renal, nefrosclerosis y enfermedades relacionadas con la hipertensi?n.
MX2009013937A 2007-07-02 2008-06-27 Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. MX2009013937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0701602 2007-07-02
PCT/SE2008/050797 WO2009005464A1 (en) 2007-07-02 2008-06-27 New use of known pharmacologically active chemical compounds

Publications (1)

Publication Number Publication Date
MX2009013937A true MX2009013937A (es) 2010-04-30

Family

ID=40226336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013937A MX2009013937A (es) 2007-07-02 2008-06-27 Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.

Country Status (12)

Country Link
US (1) US20110039935A1 (es)
EP (1) EP2173336B1 (es)
JP (1) JP5735274B2 (es)
KR (1) KR20100039874A (es)
CN (1) CN101730532B (es)
AU (1) AU2008271307B2 (es)
BR (1) BRPI0814184A2 (es)
CA (1) CA2691746C (es)
EA (1) EA018554B1 (es)
HK (1) HK1140423A1 (es)
MX (1) MX2009013937A (es)
WO (1) WO2009005464A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082009A (zh) * 2014-02-12 2021-07-09 加利福尼亚大学董事会 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
EP3007503B1 (en) 2014-03-20 2021-06-30 Huawei Device Co., Ltd. Signal transmission method, user equipment, and base station
JP2020517689A (ja) * 2017-04-25 2020-06-18 バック インスティテュート フォー リサーチ オン エイジング 寿命および健康寿命を延ばすための製剤
PE20211816A1 (es) 2018-09-25 2021-09-14 Ponce De Leon Health Designated Activity Company Proceso de elaboracion de alfa-cetoglutarato de calcio
EP3980000A4 (en) * 2019-06-10 2023-06-21 Buck Institute for Research on Aging METHODS AND COMPOSITIONS FOR MODIFYING A SECRETORY PHENOTYPE ASSOCIATED WITH SENESCENCE
JP2023533452A (ja) * 2020-06-23 2023-08-03 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 動脈瘤を処置するための求電子化合物および求電子プロドラッグ
CN117530940A (zh) * 2023-10-11 2024-02-09 四川大学华西第二医院 α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
JP2000093096A (ja) * 1998-09-21 2000-04-04 Snow Brand Milk Prod Co Ltd ゼリー状食品
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
CN1203168C (zh) * 2001-08-17 2005-05-25 杨志东 一种制备食疗保健醋的方法及用该方法生产的食疗保健醋
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US7194301B2 (en) * 2003-10-06 2007-03-20 Transneuronic, Inc. Method for screening and treating patients at risk of medical disorders
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
US20100104548A1 (en) * 2005-06-24 2010-04-29 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus

Also Published As

Publication number Publication date
WO2009005464A1 (en) 2009-01-08
EP2173336A4 (en) 2010-11-10
CA2691746C (en) 2016-02-02
JP2010532348A (ja) 2010-10-07
HK1140423A1 (en) 2010-10-15
US20110039935A1 (en) 2011-02-17
EA018554B1 (ru) 2013-08-30
EA201070084A1 (ru) 2010-10-29
AU2008271307A1 (en) 2009-01-08
CN101730532A (zh) 2010-06-09
CA2691746A1 (en) 2009-01-08
KR20100039874A (ko) 2010-04-16
EP2173336B1 (en) 2016-03-30
CN101730532B (zh) 2012-05-30
AU2008271307B2 (en) 2013-10-24
EP2173336A1 (en) 2010-04-14
JP5735274B2 (ja) 2015-06-17
BRPI0814184A2 (pt) 2015-03-03

Similar Documents

Publication Publication Date Title
MX2009013937A (es) Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
NZ715983A (en) Vasoprotective and cardioprotective antidiabetic therapy
NZ596041A (en) Use of guanethidine for treating hypertension by local vascular delivery
MX2010002565A (es) Acidos 6-fenilnicotinicos substituidos y su uso.
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
WO2011031493A3 (en) Galectin-3 and cardiac resynchronization therapy
JP2010532348A5 (es)
WO2006104086A1 (ja) 血栓症治療剤
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
NZ596747A (en) Crystalline form of pemirolast
MY156174A (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2005123096A3 (en) Compositions and methods of use of dimer digallates
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
CN104001175B (zh) 一种治疗慢性心力衰竭的药物组合物及其应用
CN102283831B (zh) 一种治疗冠心病的西药复方及用途
JP5982715B2 (ja) 抗高血圧薬組成物
Minushkina Calcium antagonists in arterial hypertension treatment: specifics of lercanidipine
TW200738654A (en) Alkoxymethyl-substituted benzoic acid derivatives, process for their preparation and their use as medicaments
KR101104773B1 (ko) 신남알코올을 함유하는 고혈압 예방 및 치료용 조성물
Dhalla REVERSAL OF CARDIAC REMODELING IN HEART FAILURE BY ALPHA-ADRENOCEPTOR BLOCKADE
Brownlee Compartment syndrome: case report
TW200635575A (en) Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome
TH104398A (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด
Fogari et al. Interaction of Clonidine and Beta Blocking Agents in the Treatment of Essential Hypertension

Legal Events

Date Code Title Description
FG Grant or registration